GALNT2 sustains glioma stem cells by promoting CD44 expression

Area of Science:

• Neuro-oncology
• Cancer Biology
• Molecular Therapeutics

Background:

• Glioblastoma (GBM) is a highly malignant and treatment-resistant primary brain tumor.
• Glioblastoma stem cells (GSCs) are crucial for tumor initiation, maintenance, and recurrence.

Purpose of the Study:

• To investigate the role of polypeptide N-acetylgalactosaminyltransferase 5 (GALNT2) in GBM pathogenesis.
• To identify therapeutic strategies targeting GALNT2 for GBM treatment.

Main Methods:

• Assessed GALNT2 expression in GBM patient samples and GSCs.
• Investigated the functional role of GALNT2 in GSCs proliferation, self-renewal, and invasion.
• Examined the transcriptional regulation of GALNT2 by STAT3.
• Screened for and evaluated a GALNT2 inhibitor in vitro and in vivo.

Main Results:

• GALNT2 expression is upregulated in GBM, IDH1 wildtype glioma, and GSCs, correlating with poor prognosis.
• Targeting GALNT2 inhibits GSCs proliferation, self-renewal, and invasion by repressing CD44.
• STAT3 directly binds to the GALNT2 promoter, activating its transcription.
• A novel GALNT2 inhibitor effectively suppresses GSCs self-maintenance both in vitro and in vivo.

Conclusions:

• GALNT2 plays a critical role in GSCs self-maintenance and GBM progression.
• STAT3-mediated transcriptional activation of GALNT2 is a key mechanism in GBM.
• GALNT2 inhibition represents a promising therapeutic avenue for glioblastoma.